Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Acute Myeloid Leukemia (AML) Clinical Trial

Official title:

Phase 1 Study of Niclosamide (ANA001) in Pediatric Patients With Relapsed and Refractory AML

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05188170
• Other study ID #: IRB-61916
• Secondary ID: PEDSHEMAML000764
• Status: Recruiting
• Phase: Phase 1
• Start date: November 21, 2022
• Est. completion date: December 2026

Study information

• Verified date: January 2024
• Source: Stanford University
• Contact: Nancy Sweeters
• Phone: 650-724-4042
• Email: nks2016[@]stanford.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 16
• Est. completion date: December 2026
• Est. primary completion date: July 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 25 Years

Eligibility

Inclusion Criteria:

• Prior morphologically confirmed diagnosis of AML based on WHO Criteria
• Has previously failed all available and suitable therapies for AML Disease relapse or the presence of refractory disease after = 2 cycles of chemotherapy must be documented by bone marrow (BM) examination demonstrating > 5% blasts in the BM not attributable to another cause. Administration of hydroxyurea 10 to 20 mg/kg/day PO (maximum 1000 mg PO BID) to control high WBC count is permitted.
• Age = 2 and = 25 years
• Body surface area (BSA) = 2.10 m2, calculated per the Mostellar formula
• Must be able to tolerate po or ng medications.
• Performance status:
• Subject age = 16 years old: Lansky score = 50 > 16 years old: Karnofsky score = 50%
• Life expectancy of greater than 4 weeks
• Platelets = 10,000/mm3 (for subjects with platelets < 10,000/mm3 at baseline, platelet transfusion support is allowed)
• Serum creatinine = 2.0 mg/dL or estimated creatinine clearance = 30 mL/min (Cockcroft Gault) within 14 days prior to treatment initiation
• Total bilirubin = 2.0 x Institutional upper limit of normal (ULN) within 14 days prior to treatment initiation, unless the elevation is due primarily to elevated unconjugated hyperbilirubinemia secondary to Gilbert's syndrome or hemolysis or non hepatic origin, and not to liver dysfunction
• SGOT (AST) = 3.0 x ULN and SGPT (ALT) = 3.0 x ULN within 14 days prior to treatment initiation
• Females of reproductive potential (WOCBP) must have a negative pregnancy test within 14 days prior to study treatment.
• WOCBP must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) for the duration of study participation
• Men only: Men must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) prior to the study treatment (from date of consent), for the duration of study participation, and 30 days after completion of niclosamide administration
• Ability to understand the purpose and risks of the study and the willingness to sign a written informed consent document containing an authorization to use protected health information (in accordance with national and local subject privacy regulations

Exclusion Criteria:

• Received anticancer therapy (chemotherapy, immunotherapy, radiotherapy, or investigational therapy) within 2 weeks prior to starting study treatment. Administration of hydroxyurea 10 to 20 mg/kg/day PO (maximum 1000 mg PO BID) to control high WBC is permitted.
• Receiving any other investigational agents.
• Unresolved toxicities due to prior anticancer therapy, defined as not having resolved to Grade 0 or 1 (by CTCAE version 5 criteria), unless otherwise defined in the inclusion/exclusion criteria with the exception of alopecia
• Acute promyelocytic leukemia (French American British Class M3 AML)
• Known active central nervous system (CNS) leukemia; subjects can enroll on study if CNS disease can be cleared with intrathecal chemotherapy, in the judgement of the treating physician
• Prior bone marrow transplant presenting with active uncontrolled graft versus host disease (GvHD)
• Known congenital bleeding disorders, including but not limited to hemophilia
• Known active uncontrolled systemic infection
• Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, uncontrolled symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction, at the time of study entry
• Inability to receive administration of niclosamide in the available formulation(s)
• Uncontrolled intercurrent illness including, but not limited to, uncontrolled active infection, or psychiatric illness/social situations that would limit compliance with study requirements
• Lactating or pregnant female
• Known active hepatitis C

Related Conditions & MeSH terms

• Acute Myeloid Leukemia (AML)
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Niclosamide
Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy

Locations

Country	Name	City	State
United States	Stanford University	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicity	Dose-limiting toxicities (DLTs) are defined as any events = Grade 3 that are at least possibly, probably, or definitely related to niclosamide treatment	30 days
Secondary	Efficacy of niclosamide treatment clinical response	Clinical response is defined as any of the following.; Complete response (CR) = < 5% blasts in BM, with no evidence of extramedullary disease.; Partial response (PR) = = 5% to = 25% blasts in BM with decrease in BM blast percentage by 50%, and no evidence of extramedullary disease.; Resistant disease with clinical benefit (RD-CB) = either = 5% to = 25% blasts in BM OR a decrease in blast percentage by 50%, either with no evidence of extramedullary disease.; No response (NR) is defined as BM disease that does not fall into the above categories	8 weeks